News

The FDA has granted a full approval and label update to ponatinib (Iclusig) for patients with chronic phase (CP), accelerated phase, or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Renowned oncologist Charles G. Drake, MD, PhD, has joined NewYork-Pesbyterian/Columbia University Medical Center (CUMC).

Researchers are currently investigating the use of tropomyosin receptor kinase (TRK) inhibitor entrectinib (RXDX-101) to treat patients with relapsed or refractory solid tumors or primary tumors of the central nervous system.

Breelyn Wilky, MD, recently sat down <em>Targeted Oncology</em> to discuss recent findings of a trial investigating axitanib and pembrolizumab in soft tissue sarcomas, as well as the role she envisions for immunotherapy in the treatment of sarcoma.

The European Commission has granted a conditional approval to ixazomib (Ninlaro) in combination with lenalidomide and dexamethasone for adult patients with multiple myeloma.

Findings of a new study revealed that less than half of patients with advanced cervical cancer are receiving all 3 of the therapies considered standard of care (SOC) for the disease.

Robert A. Figlin, MD has been appointed the deputy director of the Integrated Oncology Service Line at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center.

Raoul Concepcion, MD, director, Comprehensive Prostate Center, recently sat down with <em>Targeted Oncology </em>to discuss his treatment decisions for 2 patient scenarios in prostate cancer.

Clinical trial findings from the past year will likely have a game-changing effect on the multiple myeloma landscape, according to Rafael Fonseca, MD.

Immunotherapy has potential in anaplastic thyroid cancer, but it presents a challenge because of the length of time it takes to have an effect. Maria Cabanillas, MD, discusses an upcoming clinical trial that is combining immunotherapy with targeted therapy, that may offer a solution.

According to updated study findings, pembrolizumab (Keytruda) reduced the size of tumors in patients with a subtype of soft tissue sarcoma.

Daratumumab (Darzalex)&nbsp;has received FDA approval in combination with lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone for patients with relapsed multiple myeloma following at least 1 prior therapy.

Based on encouraging efficacy signals and safety data from separate trials exploring the PD-1 inhibitor pembrolizumab (Keytruda) and the PD-L1 inhibitor durvalumab (MEDI4736), there is a role for checkpoint inhibitors in the treatment of glioblastoma multiforme (GBM).

The antibody drug conjugate ABT-414 has shown promising results for the treatment of patients with EGFR-amplified, recurrent glioblastoma (GBM).

Findings from a recent phase II study&nbsp;showed the PD-L1 inhibitor durvalumab generated durable responses in bevacizumab-na&iuml;ve patients with recurrent glioblastoma multiforme (GBM).

Researchers are hoping that a proposed phase II study exploring use of the Optune system in patients with recurrent grade III malignant glioma will expand the indications for the tumor treating fields device.

The FDA has issued a complete response letter to&nbsp;Spectrum Pharmaceuticals for apaziquone (EOquin; Qapzola) in bladder cancer.&nbsp;<br /> &nbsp;

A lower dose of radiation therapy following surgery did not improve limb function and was not found to be non-inferior compared with standard dose radiation 2 years post procedure in patients extremity soft tissue sarcoma.&nbsp;

An expert panel, consisting of the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology&nbsp;issued comprehensive, evidence-based guidelines for clinicians and pathologists regarding the testing of HER2 status for patients with gastroesophageal adenocarcinoma.&nbsp;

If an overall survival advantage is found for patients receiving first-line FOLFOX6 with or without bevacizumab plus Yttrium-90 resin microspheres for liver metastatic colorectal cancer.

Practitioners received insight into treating patients across the GI field during the GI cancers track at the 2016 Chemotherapy Foundation Symposium.

The FDA has granted a priority review to the multikinase inhibitor midostaurin as a treatment for patients with newly-diagnosed&nbsp;<em>FLT3</em>-mutated acute myeloid leukemia or advanced systemic mastocytosis.

The addition of the PD-L1 inhibitor atezolizumab to the MEK inhibitor cobimetinib and the BRAF inhibitor vemurafenib induced a high response rate for patients with&nbsp;<em>BRAF</em>-mutant unresectable melanoma.

Treatment with&nbsp;the BRAF inhibitor encorafenib combined with the MEK inhibitor binimetinib improved median progression-free survival by 7.6 months&nbsp;compared with monotherapy with vemurafenib for patients with&nbsp;<em>BRAF</em>-mutant unresectable melanoma.

The European Commission has approved the CDK4/6 inhibitor palbociclib as a treatment for adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer, either in combination with an aromatase inhibitor in the frontline setting or combined with fulvestrant after progression on endocrine therapy.

The FDA has granted a breakthrough therapy designation to the brentuximab vedotin for the treatment of patients with CD30-positive mycosis fungoides or primary cutaneous anaplastic large cell lymphoma following at least 1 prior systemic therapy.&nbsp;<br /> &nbsp;

The PD-1 inhibitor nivolumab extended overall survival versus placebo for patients who were refractory or intolerant to standard therapy&nbsp;with unresectable, advanced, or recurrent gastric cancer, according to topline data from the phase III ONO-4538-12 trial.

The FDA has approved the PD-1 inhibitor nivolumab as a treatment for patients with metastatic or recurrent squamous cell carcinoma of the head and neck following progression on platinum-based therapy.